[ Price : $8.95]
FDA approves the second generic copy of abortifacient mifepristone, a move that prompted mixed reactions from lawmakers and advoca...[ Price : $8.95]
FDA posts a five-item FDA Form-483 after inspecting Covid-19 vaccine maker Serum Institute of Indias Maharashtra manufacturing fac...[ Price : $8.95]
Rocket Pharmaceuticals withdraws its BLA for RP-L102 (mozafancogene autotemcel), an investigational gene therapy for treating Fanc...[ Price : $8.95]
Amgen says its Repatha met the primary endpoints in a landmark Phase 3 trial, making it the only PCSK9 inhibitor to demonstrate a ...[ Price : $8.95]
FDA posts a four-item Form FDA 483 that was issued to Laboratorios Grifols after a 7/2024 inspection of the firms drug manufacturi...[ Price : $8.95]
FDA accepts for review a Daiichi Sankyo and AstraZeneca supplemental BLA for Enhertu use followed by paclitaxel, trastuzumab, and ...[ Price : $8.95]
FDA approves Jazz Pharmaceuticals Zepzelca (lurbinectedin) in combination with Genentechs Tecentriq or Tecentriq Hybreza for the m...[ Price : $8.95]
FDA grants Bristol Myers Squibb fast-track status for its investigational Alzheimers therapy BMS-986446.